Does triple antiplatelet therapy reduce stroke recurrence and its severity in patients with non-cardioembolic ischaemic stroke or TIA compared to guideline therapy?
3096 patients within 48 hours of non-cardioembolic ischaemic stroke or TIA. Subgroup analysis based on symptomatic ipsilateral carotid stenosis (<30%; 30-50%; 50-70%; >70%).
Triple antiplatelet therapy (aspirin-clopidogrel-dipyridamole) for 30 days
Guideline therapy (clopidogrel, or aspirin-dipyridamole) for 30 days
Stroke recurrence and its severity using the modified Rankin Scale (mRS) at day 90hard clinical
In patients with recent non-cardioembolic stroke or TIA, triple antiplatelet therapy did not improve stroke recurrence or severity at 90 days compared to guideline therapy, even in those with severe symptomatic carotid stenosis.
Abstract Background and aims Dual antiplatelet therapy reduces early recurrence in patients with acute non-cardioembolic minor ischaemic stroke or transient ischaemic attack (TIA). The effect of triple antiplatelet therapy in the presence of symptomatic carotid stenosis is unknown. We sought to assess the effect of triple vs. guideline antiplatelet therapy using data from the Triple Antiplatelet for Reducing Dependency after Ischaemic Stroke (TARDIS) trial. Methods TARDIS randomised 3096 patients within 48 hours of non-cardioembolic ischaemic stroke or TIA to triple antiplatelet therapy (aspirin-clopidogrel-dipyridamole) or guideline therapy (clopidogrel, or aspirin-dipyridamole) for 30 days. The primary outcome was stroke recurrence and its severity using the modified Rankin Scale (mRS) at day 90. Symptomatic ipsilateral carotid stenosis was split: 30%; 30-50%; 50-70%; 70%. Data are odds ratios (OR) with 95% confidence intervals (CI) adjusted for baseline prognostic factors. Results 2839/3096 (91.7%) participants had carotid imaging. Compared with participants with 30%, 70% symptomatic stenosis participants were older, more were male, current smokers, had hypertension, presented with ischaemic stroke versus TIA, a higher NIHSS, and underwent thrombolysis. At 90 days, stroke recurrence and its severity did not differ between participants with 70% symptomatic stenosis versus those with 30% stenosis: OR 1.28, 95% CI 0.69-2.38, p=0.43. Randomisation to triple vs. guideline antiplatelet therapy did not influence the primary outcome in participants with 70% symptomatic stenosis (OR 2.32, 95% CI 0.33-16.28, p=0.40) or other symptomatic stenosis groups. Conclusions Severe symptomatic carotid stenosis was not associated with stroke recurrence and its severity; triple vs. guideline antiplatelet therapy did not effect this. Conflict of interest JP Appleton: nothing to disclose; K Krishnan: nothing to disclose; LJ Woodhouse: nothing to disclose; TJ England: nothing to disclose; N Sprigg: nothing to disclose; PM Bath: nothing to disclose
Building similarity graph...
Analyzing shared references across papers
Loading...
Jason Appleton
Kailash Krishnan
Lisa Woodhouse
European Stroke Journal
University of Nottingham
Building similarity graph...
Analyzing shared references across papers
Loading...
Appleton et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69fd7e79bfa21ec5bbf06a4f — DOI: https://doi.org/10.1093/esj/aakag023.612